Please note some content on this site is no longer supported on Internet Explorer 8, we recommend you upgrade your browser
Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients.
Targovax is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient’s own immune system to fight the cancer.
Read more on targeting cancer cells with engineered oncolytic viruses
Read more on targeting RAS mutations
Targovax’s lead peptide-based targeted immunotherapy, TG01, is a therapeutic cancer vaccine against RAS mutated cancers. TG01 is currently in a Phase I/II clinical trial in resected pancreatic cancer. In the Phase I part of the study, TG01 induced immune responses in almost all patients and had a favorable safety and tolerability profile. Encouraging interim 1 year overall survival data showed that 14 out of 15 evaluable patients were still alive after one year. This contrasts favorably with a historical 1-year overall survival rate of 75%. The trial is fully recruited (32 patients in total). Final 2 year OS results are expected in 2017/2018.
ONCOS-102 is Targovax’s lead adenovirus-based pipeline product – a purposefully engineered human serotype 5 adenovirus optimized to induce systemic anti-tumor T cell response in cancer patients. ONCOS-102 has completed a Phase I clinical study and is soon to start additional trials in several solid tumor indications. A phase I/II trial in mesothelioma has started in June 2016. In this trial, ONCOS-102 is combined with SoC chemotherapy.
ONCOS-102 showed encouraging Phase I efficacy data in a challenging patient population. In its Phase I clinical trial in heavily-pretreated patients with multiple types of solid tumors, ONCOS-102 demonstrated a stable disease (SD) rate of 40% in 10 evaluable patients. ONCOS-102 has shown to lead to a strong activation of the immune system against the cancer, which was correlated with survival.
Targovax has Orphan Drug Designation with the FDA and EMA for TG01 in pancreatic cancer and for ONCOS-102 in mesothelioma, ovarian cancer and soft tissue sarcoma.
Targovax remains committed to the discovery, development and delivery to patients of its first-in-class targeted immunotherapies.
Targovax is developing its lead peptide-based candidate, TG01, an immunotherapy targeting RAS positive cancer cells, in a Phase 2 clinical trial in pancreatic cancer. Targovax’s other RAS targeting immunotherapy, TG02, will soon enter a clinical trial in combination with the immune checkpoint inhibitor Keytruda in colorectal cancer. Targovax’s lead adenoviral candidate, ONCOS-102, has completed a Phase 1 study in solid tumors and has recently entered into a Phase I/II study in mesothelioma in combination with standard of care chemotherapy. ONCOS-102, will enter further clinical studies in the near future for the treatment of solid tumors such as melanoma as well as ovarian and prostate cancer.
Targovax is interested in discussing various forms of strategic collaboration regarding its projects.
Investor Email Alerts